Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 3.087
Filter
1.
Oncología (Ecuador) ; 31(3): 213-225, 30-diciembre-2021.
Article in Spanish | LILACS | ID: biblio-1352466

ABSTRACT

Introducción: El cáncer de endometrio, el cáncer de ovario y el cáncer cervicouterino son las neoplasias, dentro del cáncer del aparato reproductor femenino, que se consideran más frecuentes en la actualidad. La aparición de cáncer ginecológico en mujeres vírgenes demuestra que se deben consideran otras factores causales de la enfermedad, sin embargo, en nuestro país, no hay la suficiente evidencia de documentación sobre estos casos. El objetivo del presente estudio medir la prevalencia de cáncer de cuello uterino, útero y ovarios en mujeres vírgenes atendidas en un centro de referencia de Ginecología Oncológica de Guayaquil. Metodología: El estudio es observacional y transversal, se realizó en el Hospital de Especialidades Teodoro Maldonado Carbo, del Instituto Ecuatoriano de Seguridad Social, Guayaquil-Ecuador, de enero del 2013 al diciembre del 2017. Se incluyeron pacientes con cáncer cervicouterino, de útero y ovarios divididos en Grupo 1 (G1) Mujeres vírgenes y Grupo 2 (G2): Mujeres con vida sexual activa. Las variables fueron edad, órgano afectado, comorbilidades, antecedente familiar de cáncer, tipo histológico y muerte. La muestra fue no probabilística, tipo censo. Se utiliza estadística analítica, la muestra dividida en 2 grupos se compara usando Chi2. Se reporta Odds Ratio con intervalo de confianza del 95%. Resultados: En G1 fueron 44 casos y en G2 fueron 337 casos. Lo que representa una prevalencia de 11.55% (IC95% 11.38-11.71%). Cáncer de Ovario en G1 fue 29/44 casos (66%) versus 95/337 casos (28.2%) en G2 P<0.0001 con OR: 4.92 (2.53-9.60). Cáncer de endometrio en G1 13/44 casos (29.5%) versus 54/337 casos (16%) en G2, OR 2.20 (1.08-4.47) P=0.03. Cáncer cervical en G1 2/44 casos (4.5%) y en G2 188/337 casos (55.8%) OR 0.38 (0.009-0.159) P<0.0001. La mortalidad en G1 fue 30/44 casos en G2 fue 130/337 casos, OR 4.14 (2.12-8.08) P>0.0001. Conclusión: En mujeres sin antecedentes de vida sexual, existe mayor riesgo de cáncer de ovario y de endometrio y el riesgo de cáncer de cérvix se disminuye un 96%. La mortalidad de este grupo de mujeres se duplica por la mayor existencia de cáncer de ovario y endometrial.


Introduction: Endometrial cancer, ovarian cancer and cervical cancer are the neoplasias, within cancer of the female reproductive system, which are considered more frequent today. The appearance of gynecological cancer in virgin women shows that other causal factors of the disease must be considered, however, in our country, there is not enough documentary evidence on these cases. The objective of this study is to measure the prevalence of cervical, uterine and ovarian cancer in virgin women treated in a reference center for Gynecology Oncology in Guayaquil. Methodology: The study is observational and cross-sectional, it was carried out at the Teodoro Maldonado Carbo Specialties Hospital, of the Ecuadorian Social Security Institute, Guayaquil-Ecuador, from January 2013 to December 2017. Patients with cervical, uterine and cervical cancer were includ-ed. ovaries divided into Group 1 (G1) Virgin women and Group 2 (G2): Women with an active sexual life. The variables were age, affected organ, comorbidities, family history of cancer, histological type, and death. The sample was non-probabilistic, census type. Analytical statistics are used, the sample divided into 2 groups is compared using Chi2. Odds Ratio is reported with a confidence interval of 95%. Results: In G1 there were 44 cases and in G2 there were 337 cases. Which represents a prevalence of 11.55% (95% CI 11.38-11.71%). Ovarian cancer in G1 was 29/44 cases (66%) versus 95/337 cases (28.2%) in G2 P <0.0001 with OR: 4.92 (2.53-9.60). Endometrial cancer in G1 13/44 cases (29.5%) versus 54/337 cases (16%) in G2, OR 2.20 (1.08-4.47) P = 0.03. Cervical cancer in G1 2/44 cases (4.5%) and in G2 188/337 cases (55.8%) OR 0.38 (0.009-0.159) P <0.0001. Mortality in G1 was 30/44 cases in G2 it was 130/337 cases, OR 4.14 (2.12-8.08) P> 0.0001. Conclusion: In women with no history of sexual life, there is a greater risk of ovarian and endometrial cancer and the risk of cervical cancer is decreased by 96%. The mortality of this group of women doubles due to the increased existence of ovarian and endometrial cancer


Subject(s)
Humans , Female , Sexual Behavior , Uterine Cervical Neoplasms , Endometrial Neoplasms , Ovarian Neoplasms , Parity , Uterine Neoplasms
2.
Medicina (B.Aires) ; 81(4): 565-573, ago. 2021. graf
Article in Spanish | LILACS | ID: biblio-1346508

ABSTRACT

Resumen El cáncer de ovario ocupa el tercer lugar en frecuencia entre los cánceres ginecológicos en Argentina. Existe un déficit de información de esta enfermedad en nuestro país respecto al tratamiento y evolución oncológica de las pacientes. El objetivo de nuestro trabajo fue evaluar los resultados perioperatorios y oncológicos, en pacientes con tumor epitelial de ovario con estadios avanzados. Presentamos una cohorte retrospectiva en la que se evaluó la supervivencia libre de enfermedad y la supervivencia global en pacientes con tumores epiteliales de ovario tratadas en el Hospital Italiano de Buenos Aires entre junio del 2009 a junio del 2017. De 170 pacientes incluidas en el estudio, 72 (42.4%) fueron tratadas con una cirugía de citorreducción primaria (CCP), mientras que 98 (57.6%) recibieron neoadyuvancia y luego cirugía del intervalo (CI). La tasa de citorreducción óptima fue de 75% y de 79% respectivamente. No se encontraron diferencias en los resultados perioperatorios, ni en las complicaciones graves entre ambos grupos. La mediana de SLE en el grupo de CCP fue de 2.5 años (IC 95% 1.6-3.1) mientras que en el grupo de CI fue de 1.4 (IC 95% 1.2-1.7) p < 0.001. La mediana de supervivencia global fue de 5.8 años en CCP, y de 3.5 años en CI. En pacientes adecuadamente seleccionadas la CCP presenta mejores resultados oncológicos a la neoadyuvancia y CI. La selección correcta de las pacientes para tratamiento primario es fundamental para definir la conducta terapéutica.


Abstract Ovarian cancer represents the third gynecological cancer in frequency in Argentina. There is a lack of information on this pathology in our country regarding the treatment and evolution of patients who suffer it. The aim of this study was to evaluate the perioperative and oncological results in patients with advanced epithelial ovarian tumor. We present a retrospective cohort in which we evaluated disease-free survival and overall survival in patients with epithelial ovarian tumor treated at the Hospital Italiano de Buenos Aires between June 2009 and June 2017. Of 170 patients included in the study, 72 (42.4%) received primary debulking surgery (CCP), while 98 (57.6%) received neoadjuvant therapy and interval surgery (CI). The optimal cyto-reduction rate was 75% and 79% respectively. No differences were found in perioperative outcomes, or in severe complications between the two groups. The median disease-free survival in the CCP group was 2.5 years (95% CI 1.6-3.1) while in the CI group it was 1.4 (95% CI 1.2-1.7) p < 0.001. The median overall survival was 5.8 years in CPP, and 3.5 years in CI. Faced with a meticulous selection by a group of experts, patients with advanced ovarian cancer treated with CCP present better oncological results than those who received neoadjuvant therapy and CI.


Subject(s)
Humans , Female , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Retrospective Studies , Treatment Outcome , Neoadjuvant Therapy , Carcinoma, Ovarian Epithelial/pathology , Carcinoma, Ovarian Epithelial/therapy , Hospitals , Neoplasm Staging
4.
Oncol. (Guayaquil) ; 31(2): 122-130, 31 de agosto 2021.
Article in Spanish | LILACS | ID: biblio-1284441

ABSTRACT

Introducción: El trombo embolismo venoso (TEV), una complicación frecuente en pacientes con cáncer ginecológico. El objetivo del estudio fue determinar la incidencia de TEV profunda en pacientes diagnosticados con neoplasias útero ováricas en un centro de referencia oncológica en Guayaquil-Ecuador en el año 2019 (enero-diciembre). Metodología: El presente estudio observacional, de fuente retrospectiva se realizó en el servicio de estadística del Instituto Oncológico Nacional "Dr. Juan Tanca Marengo" de la Sociedad de Lucha contra el Cáncer-SOLCA, Guayaquil Ecuador. El cálculo del tamaño muestral fue probabilístico de 237 pacientes. Se incluyeron casos de pacientes con neoplasias útero ováricas y endometriales. Las variables fueron edad, localización de la neoplasia, incidencia de TEV en base a evidencia Ultrasonográfica de TEV, criterios Wels, dímero D. Se utilizó estadística descriptiva. Los porcentajes se presentan con intervalo de confianza. Resultados: Se incluyeron 237 pacientes, el grupo etario más frecuente de 40 a 59 años con el 46.4%, seguido de 60 y más años con el 34.6%; el 88.6% de los casos tuvieron cáncer de útero (cérvix ­ endometrio) y el 11.4% con cáncer de ovario. Por la clasificación de Wells, el 92% presentó riesgo moderado de TVP y 8% riesgo alto. La incidencia de trombosis venosa profunda en pacientes con cáncer útero ­ ovario fue del 6.75% (IC 6.54-6.96%). La incidencia fue estadísticamente más prevalente (P=0.01) en el grupo de mujeres con Ca de Útero que en el grupo de Ca de ovario. Conclusión: Las neoplasias útero ováricas tienen alta incidencia de trombosis venosa profunda.


Introduction: Venous thrombus embolism (VTE), a frequent complication in patients with gynecological cancer. The objective of the study was to determine the incidence of deep VTE in patients diagnosed with uterine-ovarian neoplasms in an oncology referral center in Guayaquil-Ecuador in 2019. Methodology: The present observational study, from a retrospective source, was carried out in the statistics service of the National Oncological Institute "Dr. Juan Tanca Marengo" from the Society for the Fight Against Cancer-SOLCA, Guayaquil Ecuador. The calculation of the sample size was probabilistic of 237 patients. Cases of patients with uterine-ovarian and endometrial neoplasms were included. The variables were age, location of the neoplasm, incidence of VTE based on ultrasound evidence of VTE, Wels criteria, D-dimer. Descriptive statistics were used. The percentages are presented with a confidence interval. Results: 237 patients were included, the most frequent age group 40 to 59 years with 46.4%, fol-lowed by 60 and over with 34.6%; 88.6% of the cases had uterine cancer (cervix - endometrium) and 11.4% with ovarian cancer. According to the Wells classification, 92% had a moderate risk of DVT and 8% had a high risk. The incidence of deep vein thrombosis in patients with uterine-ovarian cancer was 6.75% (CI 6.54-6.96%). The incidence was statistically more prevalent (P=0.01) in the group of wom-en with Uterus Ca than in the ovarian Ca group. Conclusion: Utero-ovarian neoplasms have a high incidence of deep vein thrombosis.


Introdução: Embolia por trombo venoso (TEV), uma complicação frequente em pacientes com câncer ginecológico. O objetivo do estudo foi determinar a incidência de TEV profundo em pacientes com diagnóstico de neoplasias uterino-ovarianas em um centro de referência em oncologia em Guayaquil-Equador em 2019 (janeiro-dezembro). Metodologia: O presente estudo observacional, de fonte retrospectiva, foi realizado no serviço de estatística do Instituto Oncológico Nacional "Dr. Juan Tanca Marengo "da Sociedade de Luta contra o Câncer-SOLCA, Guayaquil, Equador. O cálculo do tamanho da amostra foi probabilístico de 237 pacientes. Foram incluídos casos de pacientes com neoplasias uterino-ovarianas e endometriais. As variáveis ​​foram idade, localização da neoplasia, incidência de TEV com base em evidências ultrassonográficas de TEV, critérios de Wels, dímero D. Foi utilizada estatística descritiva. As porcentagens são apresentadas com intervalo de confiança. Resultados: foram incluídos 237 pacientes, a faixa etária mais frequente de 40 a 59 anos com 46,4%, seguida de 60 e mais anos com 34,6%; 88,6% dos casos tiveram câncer de útero (colo do útero - endométrio) e 11,4% de câncer de ovário. De acordo com a classificação de Wells, 92% apresentaram risco moderado de TVP e 8% risco alto. A incidência de trombose venosa profunda em pacientes com câncer de útero-ovário foi de 6,75% (IC 6,54-6,96%). A incidência foi estatisticamente mais prevalente (P = 0,01) no grupo de mulheres com Ca no útero do que no grupo de Ca ovariana. Conclusão: As neoplasias útero-ovarianas apresentam alta incidência de trombose venosa profunda.


Subject(s)
Humans , Female , Adult , Middle Aged , Ovarian Neoplasms , Uterine Cervical Neoplasms , Endometrial Neoplasms , Venous Thrombosis , Embolism and Thrombosis
5.
Arch. argent. pediatr ; 119(5): e545-e549, oct. 2021. ilus
Article in Spanish | LILACS, BINACIS | ID: biblio-1292803

ABSTRACT

La hipercalcemia asociada a tumores malignos es una entidad poco frecuente en pediatría (0,5-1,3 % de los cánceres pediátricos). Es causada por diferentes mecanismos fisiopatológicos y los síntomas de presentación suelen ser inespecíficos, pero potencialmente graves. Presentamos un caso clínico de una paciente de 12 años con diagnóstico de disgerminoma ovárico bilateral. La enfermedad se presentó con hipercalcemia grave, tratada con hiperhidratación asociada a diuréticos de asa, bifosfonatos y, por último, la resección quirúrgica del tumor, que permitió la resolución definitiva del cuadro. A pesar de tratarse de un trastorno hidroeléctrico poco habitual en pediatría, dada la potencial gravedad de la hipercalcemia, es importante la detección y el tratamiento tempranos, con el fin de evitar complicaciones en el corto y el largo plazo


Hypercalcemia associated with malignant tumors is a rare entity in pediatrics (0.5-1.3 % of pediatric cancers). It responds to different pathophysiological mechanisms and the typical symptoms shown are usually nonspecific, but potentially serious. We present a clinical case of a 12-year-old patient with a bilateral ovarian dysgerminoma who was diagnosed with severe hypercalcemia at the onset, which required hyperhydration associated with loop diuretics, bisphosphonates and, eventually, the tumor resection surgery that allowed the final resolution of the clinical picture.Despite being a rare hydroelectric disorder in pediatrics, given the potential severity of hypercalcemia, early detection and treatment are important in order to avoid potential short- and long-term complications.


Subject(s)
Humans , Female , Child , Ovarian Neoplasms/complications , Ovarian Neoplasms/diagnosis , Dysgerminoma/complications , Dysgerminoma/diagnosis , Hypercalcemia/diagnosis , Hypercalcemia/etiology , Pediatrics
6.
Arch. argent. pediatr ; 119(2): e149-e152, abril 2021. tab
Article in Spanish | LILACS, BINACIS | ID: biblio-1152046

ABSTRACT

Los tumores ováricos, a diferencia de lo que sucede en la edad adulta, son infrecuentes en la población pediátrica. Predomina la estirpe germinal, con altas tasas de supervivencia. El objetivo de este estudio es presentar la epidemiología, clínica, diagnóstico y tratamiento de las pacientes de 0-15 años con diagnóstico, entre 2007 y 2017, de tumor ovárico en nuestro centro. Fueron 8 los casos encontrados de 171 tumores diagnosticados (el 4,7 %), con edad media de presentación de 12,5 años. Predominaban, al momento del debut, alteraciones menstruales, dolor abdominal y aumento de perímetro abdominal. Fueron de tipo germinal 6/8, y el teratoma maduro fue el más frecuente. Todas se diagnosticaron con ecografía abdominal, y se confirmó el diagnóstico en 7/8 con resonancia magnética. Se intervinieron todos los casos; predominó la salpingo-ooforectomía, y una paciente precisó quimioterapia adyuvante. La supervivencia libre de enfermedad fue del 100 %.


Unlike adults, ovarian tumors are infrequent in the pediatric population, predominating the germ line at this age, with high survival rates. The objective is to present the epidemiological, clinical, diagnosis and therapeutic characteristics of 0 to 15-year-old patients diagnosed with ovarian tumor in our center between 2007 and 2017.Eight cases out of 171 diagnosed tumors (4.7 %) were found, with a mean age of presentation of 12.5 years. At the moment of diagnosis, menstrual disturbances, abdominal pain and an increase in abdominal circumference predominated. Six out of eight were germ cell tumors, being the mature teratoma the most frequent one. All cases were diagnosed with abdominal ultrasound scan, confirmed in 7/8 cases with magnetic resonance imaging. All cases underwent surgery, predominating salpingo-oophorectomy with one patient requiring adjuvant chemotherapy. Disease-free survival was 100 %.


Subject(s)
Humans , Female , Child , Adolescent , Ovarian Neoplasms/diagnostic imaging , Neoplasms, Germ Cell and Embryonal , Ovarian Neoplasms/surgery , Biomarkers, Tumor , Retrospective Studies , Salpingo-oophorectomy
7.
Femina ; 49(1): 6-11, 20210131. ilus
Article in Portuguese | LILACS | ID: biblio-1146943

ABSTRACT

Este artigo visa apresentar ao médico ginecologista (clínico e/ou cirurgião), de forma prática, a normatização internacional da prática da ultrassonografia ginecológica para avaliação das massas anexiais. Desde 2000, o grupo europeu IOTA (International Ovarian Tumor Analysis) vem colhendo dados e difundindo conhecimento nessa área, de forma a padronizar o exame ultrassonográfico. Quais descritores ecográficos devem ser valorizados, como devem ser descritos e medidos, como aplicar o estudo Doppler e como interpretar a presença ou ausência desses descritores ecográficos na diferenciação das massas anexiais benignas de malignas, inferindo o risco de malignidade das massas, tudo isso está bem definido.(AU)


The main aim of this article is to present to gynecologists (clinicians and/or surgeons) the practical international gynecological ultrasound standardization for adnexal masses assessment. Since 2000, European group IOTA (International Ovarian Tumor Analysis) has been collecting data and disseminating knowledge in order to standardize ultrasound examination. It is already well-defined which ultrasound features should be described and measured, how power/color Doppler have to be applied and how the presence or absence of these features can differentiate benign from malign masses, inferring tumors malignancy risk.(AU)


Subject(s)
Humans , Female , Ovarian Diseases/diagnostic imaging , Ovarian Neoplasms/diagnostic imaging , Adnexal Diseases/diagnostic imaging , Ultrasonography/standards , Terminology as Topic
8.
Frontiers of Medicine ; (4): 116-124, 2021.
Article in English | WPRIM | ID: wpr-880943

ABSTRACT

Meigs' syndrome (MS), a rare complication of benign ovarian tumors, is easily misdiagnosed as ovarian cancer (OC). We retrospectively reviewed the clinical laboratory data of patients diagnosed with MS from 2009 to 2018. Serum carbohydrate antigen 125 and HE4 levels were higher in the MS group than in the ovarian thecoma-fibroma (OTF) and healthy control groups (all P < 0.05). However, the serum HE4 levels were lower in the MS group than in the OC group (P < 0.001). A routine blood test showed that the absolute counts and percentages of lymphocytes were significantly lower in the MS group than in the OTF and control groups (all P < 0.05). However, these variables were higher in the MS group than in the OC group (both P < 0.05). The neutrophil-to-lymphocyte ratio (NLR) was also significantly lower, whereas the lymphocyte-to-monocyte ratio was higher in the MS group than in the OC group (both P < 0.05). The NLR, platelet-to-lymphocyte ratio, and systemic immune index were significantly higher in the MS group than in the OTF and control groups (all P < 0.05). The hypoxia-inducible factor-1 mRNA levels were also significantly higher, whereas the glucose transporter 1, lactate dehydrogenase, and enolase 1 mRNA levels were lower in peripheral CD4


Subject(s)
Carcinoma, Ovarian Epithelial , Female , Fibroma , Humans , Laboratories , Meigs Syndrome/diagnosis , Ovarian Neoplasms , Retrospective Studies
9.
Article in Chinese | WPRIM | ID: wpr-880834

ABSTRACT

OBJECTIVE@#To explore the mechanism by which ginsenoside 20(S)-Rg3 upregulates the expression of tumor suppressor von Hippel-Lindau (VHL) gene in ovarian cancer cells.@*METHODS@#Ovarian cancer cell line SKOV3 treated with 20(S)-Rg3 were examined for mRNA and protein levels of VHL, DNMT1, DNMT3A and DNMT3B by real-time PCR and Western blotting, respectively. The changes in VHL mRNA expression in SKOV3 cells in response to treatment with 5-Aza-CdR, a DNA methyltransferase inhibitor, were detected using real-time PCR. VHL gene promoter methylation was examined with methylation-specific PCR and VHL expression levels were determined with real-time PCR and Western blotting in non-treated or 20(S)-Rg3-treated SKOV3 cells and in 20(S)-Rg3-treated DNMT3A-overexpressing SKOV3 cells. VHL and DNMT3A protein levels were detected by immunohistochemistry in subcutaneous SKOV3 cell xenografts in nude mice.@*RESULTS@#Treatment of SKOV3 cells with 20(S)-Rg3 significantly upregulated VHL and downregulated DNMT3A expressions at both the mRNA and protein levels (@*CONCLUSIONS@#Ginsenoside 20(S)-Rg3 upregulates VHL expression in ovarian cancer cells by suppressing DNMT3A-mediated DNA methylation.


Subject(s)
Animals , Cell Line, Tumor , DNA Methylation , Female , Gene Expression , Ginsenosides/pharmacology , Humans , Mice , Mice, Nude , Ovarian Neoplasms/genetics , Promoter Regions, Genetic , Von Hippel-Lindau Tumor Suppressor Protein/genetics
10.
Autops. Case Rep ; 11: e2021249, 2021. graf
Article in English | LILACS | ID: biblio-1153185

ABSTRACT

Collision tumors have been reported in various organs like the gastrointestinal tract, lung, skin, adrenals, central nervous system, lymph nodes, uterus, but are rarely seen in the ovary. Collision tumors are two histologically distinct neoplasms in the same organ without any intermixture between them. Here we present a case of a collision tumor of the ovary represented by a mucinous cystadenoma and teratoma. It is imperative for a surgical pathologist to correctly diagnose the collision tumor components and differentiate them from mixed tumors as it will dictate the appropriate treatment based on the individual biological aggressiveness of each component.


Subject(s)
Humans , Female , Adult , Teratoma/pathology , Cystadenoma, Mucinous/pathology , Ovarian Neoplasms/complications , Diagnosis, Differential
11.
Autops. Case Rep ; 11: e2021248, 2021. graf
Article in English | LILACS | ID: biblio-1153175

ABSTRACT

Metastatic gallbladder carcinoma to the ovaries is occasional but a recognized entity. It can mimic, clinical and morphologically, a primary ovarian tumor, challenging the diagnosis. We present the case of a patient with a lump in the hypogastrium extending into the right iliac fossa and was found to have abdominopelvic cystic lesion with enhancing solid components and multiple sub-centimetric and ill-defined abdominal lymph nodes. Also, subpleural and parenchymal nodules in the lungs were present. She subsequently underwent a laparotomy. Cholecystectomy was also done due to pre-existing symptomatic biliary lithiasis. The histologic report described the ovarian involvement as metastases from a gallbladder carcinoma. The presentation of ovarian metastases can challenge the diagnosis. Hence, careful evaluation of the digestive tract and judicious use of immunohistochemistry should be considered in patients presenting with ovarian masses.


Subject(s)
Humans , Female , Middle Aged , Ovarian Neoplasms/pathology , Carcinoma , Gallbladder/abnormalities , Immunohistochemistry , Neoplasm Metastasis
13.
Article in Chinese | WPRIM | ID: wpr-878928

ABSTRACT

Based on the PI3K/Akt signaling pathway, this study aimed to observe the proliferation and apoptosis of ovarian cancer SKOV3 cells at different concentrations of icaritin, in order to explore the possible molecular mechanisms. The research object was ovarian cancer SKOV3 cells. The cells were divided into the control group and icaritin groups(5, 10, 20 μmol·L~(-1)), and administrated with drugs for 48 hours. The cell counting kit-8(CCK-8)assay was used to detect the inhibitory effect of icaritin on the proliferation of ovarian cancer SKOV3 cells. The proliferation ability of the SKOV3 cells was detected by EdU assay. Hoechst 33342 fluorescence staining was used to observe the apoptotic morphology of SKOV3 cells in each group. The distribution of cell cycle and the apoptosis rate of each group were detected by flow cytometry. Quantitative Real-time PCR was used to detect mRNA expressions of PTEN, PI3K, Akt in each group of cells. Protein expressions of PTEN, PI3K, Akt and p-Akt were measured by Western blot. The results showed that the cell inhibition rates of icaritin groups were significantly increased compared with the control group(P<0.05). The rates of EdU-positive cells of icaritin groups were significantly decreased(P<0.05). SKOV3 cells in icaritin groups showed morphological changes of apoptosis. Apoptosis rates of icaritin groups were significantly increased(P<0.05). The proportions of cells in G_0/G_1 phase of icaritin groups were decreased(P<0.05), while the proportions of S phase cells were increased(P<0.05). The gene and protein expressions of PTEN in icaritin groups were elevated(P<0.05). The gene expressions of PI3K and Akt in icaritin groups were down-regulated(P<0.05). The protein expression of PI3K and p-Akt in icaritin groups were reduced(P<0.05). These results indicated that icarin may inhibit the proliferation of ovarian cancer SKOV3 cells in vitro, induce cell apoptosis and affect the cycle distribution of cells by inhibiting the PI3K/Akt signaling pathway.


Subject(s)
Apoptosis , Cell Line, Tumor , Cell Proliferation , Female , Flavonoids , Humans , Ovarian Neoplasms/genetics , Phosphatidylinositol 3-Kinases/genetics , Proto-Oncogene Proteins c-akt/genetics
14.
Article in English | WPRIM | ID: wpr-878331

ABSTRACT

Objective@#The underlying mechanism of Ezrin in ovarian cancer (OVCA) is far from being understood. Therefore, this study aimed to assess the role of Ezrin in OVCA cells (SKOV3 and CaOV3) and investigate the associated molecular mechanisms.@*Methods@#We performed Western blotting, reverse transcription-quantitative polymerase chain reaction, MTT, cell colony, cell wound healing, transwell migration and invasion, RhoA and Rac active pull down assays, and confocal immunofluorescence experiments to evaluate the functions and molecular mechanisms of Ezrin overexpression or knockdown in the proliferation and metastasis of OVCA cells.@*Results@#The ectopic expression of Ezrin significantly increased cell proliferation, invasiveness, and epithelial-mesenchymal transition (EMT) in OVCA cells. By contrast, the knockdown of endogenous Ezrin prevented OVCA cell proliferation, invasiveness, and EMT. Lastly, we observed that Ezrin can positively regulate the active forms of RhoA rather than Rac-1 in OVCA cells, thereby promoting robust stress fiber formation.@*Conclusion@#Our results indicated that Ezrin regulates OVCA cell proliferation and invasiveness by modulating EMT and induces actin stress fiber formation by regulating Rho-GTPase activity, which provides novel insights into the treatment of the OVCA.


Subject(s)
Cell Line, Tumor , Cell Movement , Cell Proliferation , Cytoskeletal Proteins/metabolism , Epithelial-Mesenchymal Transition , Female , Gene Expression Regulation, Neoplastic , Humans , Neoplasm Invasiveness , Ovarian Neoplasms/pathology , Stress Fibers/metabolism , rhoA GTP-Binding Protein/metabolism
15.
Appl. cancer res ; 40: 1-9, Oct. 19, 2020. ilus, tab
Article in English | LILACS, Inca | ID: biblio-1281398

ABSTRACT

Background: Ovarian cancer is the most common gynecological malignancy. In patients with advanced ovarian cancer, some biological parameters have prognostic implementations. P27kip1 is an inhibitor of a cycline-dependent kinase, its loss, can contribute to tumor progression. Objective: This study aimed to examine the importance of P27KIP1 protein in predicting the prognosis and response to neoadjuvant chemotherapy in patients with advanced ovarian epithelial cancer and to compare the outcomes of immunohistochemistry with Quantitative Real-time PCR. Patients and methods: We have studied P27KIP1expression by both immunohistochemistry and Quantitative Realtime PCR from 88 patients with advanced ovarian carcinomas undergone radical debulking surgery and received Paclitaxel followed by Cisplatin every 3 weeks for a total of 6 cycles. We also studied their association with both chemotherapy response and patient survival. Results: Nuclear expression of p27KIP1 protein was intense in 86 normal ovarian tissues and 42 of 88 carcinomas. The P27kip1mRNA expression level by qRT-PCR was very low in ovarian cancer tissues relative to its adjacent normal tissues. The results were statistically significant by both methods of determination. p27KIP1 expression was significantly related to good prognostic parameters as low stage tumors, differentiated tumors, absence of ascites, residual disease < 2 cm, and response to chemotherapy but not with histopathological type in case of determination by immunohistochemistry. Comparison of P27kip1 by both immunohistochemistry and qRTPCR with different prognostic parameters revealed no significant difference between both methods in the assessment of these parameters. In 4 years of follow-up, 20.5% of patients were alive without evidence of disease. 6.8% were alive with disease. The disease-related four -year survival rate for the whole group was 28.2%. In multivariate analysis, residual disease, histological type, tumor differentiation, ascites was of independent prognostic significance. Conclusion: In ovarian cancer, patients with loss of p27KIP1 expression are at a greater likelihood of disease progression, p27KIP1 may be used as a molecular marker to predict response to chemotherapy and prognosis. Both immunohistochemistry and qRT-PCR have equal reliability in the determination of p27 KIP1


Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Young Adult , Ovarian Neoplasms/metabolism , Cyclin-Dependent Kinase Inhibitor p27/metabolism , Carcinoma, Ovarian Epithelial/metabolism , Ovarian Neoplasms/drug therapy , Prognosis , Immunohistochemistry , Neoadjuvant Therapy , Real-Time Polymerase Chain Reaction , Carcinoma, Ovarian Epithelial/drug therapy , Neoplasm Staging
16.
Rev. inf. cient ; 99(5): 478-486, graf
Article in Spanish | LILACS | ID: biblio-1139210

ABSTRACT

RESUMEN Se presentó el caso de una adolescente de 14 años, en el servicio de Cirugía Pediátrica del Hospital Pediátrico Docente "Pedro Agustín Pérez" de Guantánamo, que refirió aumento de volumen de todo el abdomen y dolor abdominal difuso. Al examinarla se constató una tumoración visible y palpable en hemiabdomen inferior. Los estudios complementarios imagenológicos mostraron una masa ecogénica, heterogénea que ocupaba hipogastrio, más lateralizada hacia la izquierda. Tras discusión colectiva multidisciplinaria se le realizó oforectomía izquierda y los estudios anatomopatológicos confirmaron la presencia de tumor de células de la granulosa de tipo juvenil en ovario izquierdo. Técnicas quirúrgicas que permitan preservar la capacidad reproductiva a niñas con neoplasias malignas, resultan usadas ahora con frecuencia y garantizan una mayor calidad de vida.


ABSTRACT A 14-year-old girl presented to the pediatric surgery department at the Pediatric Teaching Hospital "Pedro Agustín Pérez" in Guantanamo. She reported a difuse abdominal pain and distention. The examination revealed a visible and palpable tumor in the lower hemiabdomen. Complementary imaging studies showed an ecogenic and heterogeneous mass situated in the left hypogastrium. After a multidisciplinary team meeting, an ophthalmectomy was performed, and anatomopathological studies confirmed the presence of juvenile granulosa cells tumor on the left ovary. Surgical techniques that allow girls with malignant neoplasms to preserve their reproductive capacity are now frequently used and they guarantee higher life quality.


Subject(s)
Adolescent , Ovarian Neoplasms/diagnosis , Granulosa Cell Tumor/diagnosis , Ovariectomy
17.
Rev. argent. mastología ; 39(144): 20-38, sept. 2020. tab
Article in Spanish | LILACS, BINACIS | ID: biblio-1150809

ABSTRACT

La creciente incidencia de cáncer de mama (CM) en mujeres jóvenes nos obliga a repensar la forma en como asesoramos sobre el método anticonceptivo (MAC) en estas mujeres, cuya fertilidad puede ser variablemente afectada por los tratamientos. Se les aconseja, post tratamiento, evitar la gestación temporalmente, sin embargo se observa un patrón de uso insuficiente de MAC con elección de métodos anticonceptivos poco efectivos. El objetivo de la presente revisión es indagar en al necesidad anticonceptiva de mujeres jóvenes con cáncer de mama evaluando la evidencia científica sobre qué métodos anticonceptivos pueden o no utilizar, analizando especialmente el rol del sistema intrauterino liberado de levonorgestrel y la salpingectomía de la oportunidad como cirugía anticonceptiva con potencial reducción de riesgo de cáncer de ovario en pacientes con riesgos genético. Además se pretende brindar estrategias para evitar embarazos no planificados en este grupo de pacientes.


The increasing incidence of breast cancer (BC) in young women forces us to rethink the way in which we counsel on the contraceptive method (CM) in these women, whose fertility can be variably affected by the treatments. They are advised, post treatment, to avoid pregnancy temporarily, however a pattern of insufficient contraception use is observed with the choice on ineffective contraceptive need of young women with breast cancer, evaluating the scientific evidencially analyzing the role of the levonorgestrel-releasin intrautrien system and oppotunistic salpingectomy as a contaceptive surgery with potential ovarian cancer risk reduction in patients with genetic risk. Is is also intended to provide strategies to avoid unplanned pregnancies in this group of patients.


Subject(s)
Contraception , Ovarian Neoplasms , Breast Neoplasms , Levonorgestrel , Contraceptive Agents , Fertility , Salpingectomy
18.
Rev. medica electron ; 42(4): 2111-2120, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1139301

ABSTRACT

RESUMEN Históricamente, se describen como tumores de gran tamaño aquellos que pesan más de 12 Kg, entre ellos los ginecológicos y los de ovario; sobre todo antes del advenimiento de la ecografía y en poblaciones de mala situación socioeconómica y nivel cultural, como en los países del continente africano. Se presentó un caso de quiste gigante del ovario, en una paciente de 45 años de edad, que fue atendida en el Servicio de Cirugía General del Hospital Municipal de Bocoio, provincia de Benguela, República de Angola, en el año 2015. Se presentó por un aumento de tamaño del abdomen de varios años de evolución Se le diagnosticó una masa quística dependiente de ovario, por ultrasonografía por no contar con otro medio de diagnostico imagenologico. Se confirmó a través de una laparotomía exploradora la presencia de una tumoración quística gigante del ovario de 20 kg de peso. Esta patología es poco frecuente en la actualidad debido al desarrollo de la Cirugía y de los medios de diagnósticos que permiten su detección precoz. El estudio anatomopatológico ulterior informó un cistoadenoma seroso de ovario izquierdo. La evolución de la paciente fue favorable. Se consideró un caso interesante por lo infrecuente, la poca existencia de reporte de estos casos en la literatura, sobre todo en Cuba, lo que contribuye a aportar conocimientos a la comunidad médica (AU).


ABSTRACT Through the history those tumors weighting more than 12 kg have been described as great size tumors, among them the gynecological and the ovarian ones, especially before the appearance of the ultrasonography, and among populations of bad socio-economic situation and low cultural level, like in the countries of the African continent. The authors presented the case of a giant ovarian cyst in a patient aged 45 years, who assisted in the Service of General Surgery of the Municipal Hospital of Bocolo, province of Benguela, Republic of Angola, in 1915. She arrived to the consultation due to an increase of the abdominal size of several years of evolution. By ultrasonography because there was no other mean of imaging diagnosis, the diagnosis was an ovary-dependent cystic mass. Using laparoscopy it was confirmed the presence of a giant cystic tumor of the ovary of 20 kg weight. This disease is few frequent nowadays due to the development of Surgery and diagnostic means allowing a precocious detection. The subsequent anatomopathologic study informed a serous cystadenoma of the left ovary. The patient had a satisfactory evolution. The case was considered interesting given its infrequency, the scarce existence of reports of cases like this in the literature, especially in Cuba, contributing with knowledge for the medical community (AU).


Subject(s)
Humans , Male , Female , Adult , Ovarian Cysts/surgery , Cystadenoma, Serous/diagnosis , Ovarian Cysts/diagnosis , Ovarian Neoplasms/diagnosis , Patients , Ultrasonography , Cystadenoma, Serous/surgery
19.
Rev. Assoc. Med. Bras. (1992) ; 66(8): 1134-1138, Aug. 2020. tab, graf
Article in English | LILACS, SES-SP | ID: biblio-1136337

ABSTRACT

SUMMARY Women with mutations in the BRCA 1 and 2 genes are at increased risk for ovarian and breast cancer and therefore candidates for risk-reducing surgery, including salpingo-oophorectomy and mastectomy. Risk-reducing salpingo-oophorectomy (RRSO) is considered the most effective prophylactic measure for ovarian cancer prevention in this group of patients. This procedure involves loss of ovarian function and induced menopause. Estrogen therapy is the most effective treatment for controlling vasomotor symptoms and improving the quality of life of climacteric women. However, the potential hormonal stimulation of these tumors and the risk of breast cancer are a concern regarding the safety of hormone replacement therapy (HRT) in this population. This article aims to review the current evidence regarding the potential benefits and safety of HRT after RRSO.


RESUMO Mulheres portadoras de mutações nos genes BRCA 1 e 2 possuem risco aumentado para cânceres de ovário e mama e, portanto, são candidatas às cirurgias redutoras de risco, incluindo a salpingo-ooforectomia e a mastectomia. A salpingo-ooforectomia redutora de risco (SORR) é considerada a medida profilática mais efetiva para prevenção do câncer de ovário nesse grupo de pacientes. Esse procedimento implica a perda da função ovariana e menopausa induzida. A estrogenioterapia é o tratamento mais efetivo para o controle de sintomas vasomotores e melhora da qualidade de vida de mulheres no climatério. No entanto, a potencial estimulação hormonal desses tumores e o risco de câncer de mama constituem uma preocupação com a segurança da terapia hormonal (TH) nesta população. Este artigo tem como objetivo uma revisão das evidências atuais quanto aos benefícios potenciais e segurança da TH após SORR.


Subject(s)
Humans , Female , Breast Neoplasms/therapy , Ovarian Neoplasms , Quality of Life , Ovariectomy , Risk Factors , BRCA1 Protein , BRCA2 Protein , Salpingo-oophorectomy , Mastectomy , Mutation
20.
Oncol. (Guayaquil) ; 30(2): 106-122, 31 de agosto del 2020.
Article in Spanish | LILACS | ID: biblio-1141454

ABSTRACT

Introducción:El cáncer avanzado de ovario es una de las enfermedades oncológicas de mayor mortalidad en el mundo. En el Ecuador representa aproximadamente el 0.2% de todas las muertes. Elobjetivo de del estudio fue realizar una descripción clínica retrospectiva de las mujeres con cáncer avanzado de ovario. Métodos:El presente estudio observacional, retrospectivo fue realizado en el servicio de Oncología Clínica del Instituto Oncológico Nacional "Dr. Juan Tanca Marengo" de Solca-Guayaquil.El período de estudio fue enero del 2003 al diciembre del 2007. Se incluyeron los registros de pacientes con diagnostico histopatológico del tipo de cáncer avanzado de ovario: con estadificación según FIGO III (IIIA-IIIB-IIIC) y IV. Las variables fueron descriptivas poblacionalesy clínicas: tipo histológico, estadificación, tratamiento empleado. El cálculo de la muestra es no probabilística, en la que se incluyen todos los casos posibles. Se utiliza estadística descriptiva. Resultados:79 casos ingresaron al análisis. Las mujeres de 50 a 59 años20/79 casos 25.32 (IC95%24.24-26.4%). El Adenocarcinomapapilar seroso IIIcfue la histología más prevalente 34/79 (43.04 % IC95% 41.81-44.27%). El tratamientoquimioterápico con cirugía fue el más prevalente 56/79 (70.89% IC95% 69.76-72.01). Se usó Paclitaxel+Cisplatinoen 44/79casos(55.7% IC95% 54.46-56.93%). La recidiva se presentó en 30 casos. Respuesta completa 17 casos (21.52% IC95% 20.5-22.54%), progresión en 18casos (22.78% IC95% 21.74-23.83%).Mortalidad 11 casos (13.92% IC95% 13.07-14.78%)y abandono de tratamiento32casos(40.51% IC95%39.29-41.72%). Conclusiones: La tasa de abandono es un factor que se presenta con una alta frecuenciaentre los pacientes con cáncer avanzado de ovario. Esto no permite evaluar el resultado de los tratamientos que son utilizadas para tratar los cánceres de ovario en estas etapas.


Introduction:Advanced ovarian cancer is one of the cancer diseases with the highest mortality in the world. In Ecuador it represents approximately 0.2% of all deaths. The objective of the study was to carry outa retrospective clinical description of women with advanced ovarian cancer. Methods: The present observational, retrospective study was carried out in the Clinical Oncology service of the National Oncological Institute "Dr. Juan Tanca Marengo"from Solca-Guayaquil. The study period was January 2003 to December 2007. The records of patients with histopathological diagnosis of advanced ovarian cancer were included: staging according to FIGO III (IIIA-IIIB-IIIC) and IV. The variables were descriptive, population and clinical: histological type, staging, treatment used. The calculation of the sample is non-probabilistic, which includes all possible cases. Descriptive statistics are used. Results: 79 cases entered the analysis. Women aged 50 to 59 years 20/79 cases 25.32 (95% CI 24.24-26.4%). Serous papillary adenocarcinoma IIIc was the most prevalent histology 34/79 (43.04% 95% CI 41.81-44.27%). Chemotherapy treatment with surgery was the most prevalent 56/79 (70.89% 95% CI 69.76-72.01). Paclitaxel + Cisplatin was used in 44/79 cases (55.7% 95% CI 54.46-56.93%). Recurrence occurred in 30 cases. Complete response in 17 cases (21.52% 95% CI 20.5-22.54%), progression in 18 cases (22.78% 95% CI 21.74-23.83%). Mortality 11 cases (13.92% 95% CI 13.07-14.78%) and treatment abandonment 32 cases (40.51% 95% CI 39.29-41.72%). Conclusions: The dropout rate is a factor that occurs with a high frequency among patients with advanced ovarian cancer. This does not allow evaluating the outcome of the treatments that are used to treat ovarian cancers at these stages


Subject(s)
Humans , Ovarian Neoplasms , Mortality , Drug Therapy , Ovary , Treatment Adherence and Compliance
SELECTION OF CITATIONS
SEARCH DETAIL